NASDAQ:VRCA

Verrica Pharmaceuticals Stock Forecast, Price & News

$9.12

-0.03 (-0.33 %)

(As of 12/1/2020 12:00 AM ET)

Add

Compare

Today's Range

$8.84

Now: $9.12▼

$9.30

50-Day Range

$7.41

MA: $8.49▼

$9.63

52-Week Range

$6.02

Now: $9.12▼

$17.60

Volume79,851 shs

Average Volume112,251 shs

Market Capitalization$235.90 million

P/E RatioN/A

Dividend YieldN/A

Beta2.3

Verrica Pharmaceuticals Inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts. It is also developing cantharidin-based product candidate, VP-103 for the treatment of plantar warts. The company has a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology indications. Verrica Pharmaceuticals Inc. was founded in 2013 and is headquartered in West Chester, Pennsylvania.

Beat the Market (BTM) Rank^™

3.4 Analyst's Opinion

Consensus Rating
Verrica Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $15.00, Verrica Pharmaceuticals has a forecasted upside of 64.5% from its current price of $9.12.
Amount of Analyst Coverage
Verrica Pharmaceuticals has received no research coverage in the past 90 days.

2.3 Community Rank

Outperform Votes
Verrica Pharmaceuticals has received 121 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Verrica Pharmaceuticals has received 142 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Verrica Pharmaceuticals has received 53.99% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Verrica Pharmaceuticals and other stocks. Vote “Outperform” if you believe VRCA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VRCA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Verrica Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Verrica Pharmaceuticals does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Verrica Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
40.20% of the stock of Verrica Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 33.97% of the stock of Verrica Pharmaceuticals is held by institutions.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Verrica Pharmaceuticals are expected to decrease in the coming year, from ($1.73) to ($1.89) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Verrica Pharmaceuticals is -6.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Verrica Pharmaceuticals is -6.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Verrica Pharmaceuticals has a P/B Ratio of 3.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.30 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:VRCA

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.verrica.com

Phone484-453-3300

Employees17

Debt

Debt-to-Equity RatioN/A

Current Ratio2.15

Quick Ratio2.15

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$2.52 per share

Price / Book3.62

Profitability

EPS (Most Recent Fiscal Year)($1.13)

Net Income$-28,210,000.00

Net MarginsN/A

Return on Equity-54.53%

Return on Assets-40.42%

Miscellaneous

Outstanding Shares25,866,000

Market Cap$235.90 million

Next Earnings Date3/12/2021 (Estimated)

OptionableNot Optionable

$9.12

-0.03 (-0.33 %)

(As of 12/1/2020 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive VRCA News and Ratings via Email

Sign-up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter.

Verrica Pharmaceuticals (NASDAQ:VRCA) Frequently Asked Questions

How has Verrica Pharmaceuticals' stock price been impacted by Coronavirus?

Verrica Pharmaceuticals' stock was trading at $10.52 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, VRCA stock has decreased by 13.3% and is now trading at $9.12.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Verrica Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verrica Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Verrica Pharmaceuticals or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Verrica Pharmaceuticals?

Wall Street analysts have given Verrica Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Verrica Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Verrica Pharmaceuticals' next earnings date?

Verrica Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, March 12th 2021.
View our earnings forecast for Verrica Pharmaceuticals.

How were Verrica Pharmaceuticals' earnings last quarter?

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) issued its quarterly earnings data on Monday, November, 9th. The company reported ($0.42) earnings per share for the quarter, beating analysts' consensus estimates of ($0.43) by $0.01.
View Verrica Pharmaceuticals' earnings history.

What price target have analysts set for VRCA?

4 brokers have issued 1-year price objectives for Verrica Pharmaceuticals' stock. Their forecasts range from $10.00 to $18.00. On average, they expect Verrica Pharmaceuticals' stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 64.5% from the stock's current price.
View analysts' price targets for Verrica Pharmaceuticals.

Are investors shorting Verrica Pharmaceuticals?

Verrica Pharmaceuticals saw a decrease in short interest during the month of October. As of October 30th, there was short interest totaling 1,860,000 shares, a decrease of 21.2% from the October 15th total of 2,360,000 shares. Based on an average daily volume of 170,900 shares, the days-to-cover ratio is currently 10.9 days. Currently, 14.7% of the shares of the stock are sold short.
View Verrica Pharmaceuticals' Short Interest.

Who are some of Verrica Pharmaceuticals' key competitors?

Some companies that are related to Verrica Pharmaceuticals include Syndax Pharmaceuticals (SNDX), Vectura Group (VEGPF), Provention Bio (PRVB), Protagonist Therapeutics (PTGX), Tocagen (TOCA), Calliditas Therapeutics AB (publ) (CALT), Amphastar Pharmaceuticals (AMPH), Zafgen (ZFGN), Enanta Pharmaceuticals (ENTA), DiaMedica Therapeutics (DMCAF), Esperion Therapeutics (ESPR), Omeros (OMER), VBI Vaccines (VBIV), Phibro Animal Health (PAHC) and Cara Therapeutics (CARA).
View all competitors.

What other stocks do shareholders of Verrica Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verrica Pharmaceuticals investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Novan (NOVN), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), CBL & Associates Properties (CBL), Gran Tierra Energy (GTE), Pennsylvania Real Estate Investment Trust (PEI), OrganiGram (OGI) and Aeterna Zentaris (AEZS).

Who are Verrica Pharmaceuticals' key executives?

Verrica Pharmaceuticals' management team includes the following people:

Mr. Ted White, Pres, CEO & Director (Age 55, Pay $666.19k)
Mr. A. Brian Davis, Chief Financial Officer (Age 53, Pay $342.85k)
Mr. Joe Bonaccorso, Chief Commercial Officer (Age 56, Pay $528.11k)
Dr. Gary Goldenberg M.D., Chief Medical Officer (Age 43, Pay $55k)
Mr. Christopher G. Hayes, Chief Legal Officer, Sec. & Gen. Counsel (Age 56)
Mr. Eugene Scavola, Exec. VP of Technical Operations
Dr. Bradley J. Catalone MBA, Ph.D., Head of Drug Devel.

When did Verrica Pharmaceuticals IPO?

(VRCA) raised $75 million in an IPO on Friday, June 15th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen served as the underwriters for the IPO.

What is Verrica Pharmaceuticals' stock symbol?

Verrica Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRCA."

Who are Verrica Pharmaceuticals' major shareholders?

Verrica Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.65%), Kornitzer Capital Management Inc. KS (2.61%), State Street Corp (0.90%), FinTrust Capital Advisors LLC (0.04%), Morgan Stanley (0.02%) and New York State Common Retirement Fund (0.02%). Company insiders that own Verrica Pharmaceuticals stock include A Brian Davis, Craig Ballaron, Linda Palczuk, Matt Davidson, Paul B Manning, Sean Stalfort and Ted White.
View institutional ownership trends for Verrica Pharmaceuticals.

Which institutional investors are selling Verrica Pharmaceuticals stock?

VRCA stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., New York State Common Retirement Fund, State Street Corp, and Morgan Stanley.
View insider buying and selling activity for Verrica Pharmaceuticals.

Which institutional investors are buying Verrica Pharmaceuticals stock?

VRCA stock was purchased by a variety of institutional investors in the last quarter, including Kornitzer Capital Management Inc. KS, FinTrust Capital Advisors LLC, and BNP Paribas Arbitrage SA. Company insiders that have bought Verrica Pharmaceuticals stock in the last two years include A Brian Davis, Craig Ballaron, Linda Palczuk, Paul B Manning, Sean Stalfort, and Ted White.
View insider buying and selling activity for Verrica Pharmaceuticals.

How do I buy shares of Verrica Pharmaceuticals?

Shares of VRCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Verrica Pharmaceuticals' stock price today?

One share of VRCA stock can currently be purchased for approximately $9.12.

How big of a company is Verrica Pharmaceuticals?

Verrica Pharmaceuticals has a market capitalization of $235.90 million. The company earns $-28,210,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis. Verrica Pharmaceuticals employs 17 workers across the globe.

What is Verrica Pharmaceuticals' official website?

The official website for Verrica Pharmaceuticals is www.verrica.com.

How can I contact Verrica Pharmaceuticals?

Verrica Pharmaceuticals' mailing address is 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380. The company can be reached via phone at 484-453-3300 or via email at [email protected]

This page was last updated on 12/1/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings